Canadian Pharma, Biotech and Life Sciences Stocks

Martello is benefiting from “the Bruce Linton effect”, PI says

Its stock having tripled since co-Chairman Bruce Linton parted ways with Canopy Growth Corp, Martello Technologies (Martello Technologies News, Stock Quote, Chart TSXV:MTLO) is now in a much better place to ramp up with some M&A, says PI Financial analyst David Kwan. Kawn today provided an intraday ...

Bellus Health gets new $4.10 price target at Mackie Research Capital

Recent shifts in the competitive landscape have Mackie Research Capital analyst André Uddin raising his price target on Bellus Health (Bellus Health News, Stock Quote, Chart TSX:BLU). Uddin says in the landscape of chronic cough treatments, P2X3 inhibitors are showing the most promise and advanced ...

Canopy Growth’s Bruce Linton say his exit was not entirely unexpected

His tenure at the helm of Canada’s biggest pot co may be over but Bruce Linton is still cheerleading for the emerging sector which for many years now had Linton as its primary spokesperson and key visionary. This week, news broke that Canopy Growth’s board of directors had asked Linton to step ...

Sernova Corporation has an upside of 317 per cent, Echelon says

Impressive interim outcome data from Sernova Corporation (Sernova Corporation News, Stock Quote, Chart TSXV:SVA) has Echelon Wealth Partners analyst Douglas Loe staying bullish on the regenerative medicine tech company. In a Wednesday update to clients, Loe reiterated his “Speculative Buy” rati ...

Time to hop on board Acasti Pharma, says Mackie Research

With its best-in-class omega-3 drug CaPre currently in Phase III trials, Acasti Pharma (Acasti Pharma News, Stock Quote, Chart TSXV:ACST) is ready for liftoff, says Mackie Research Capital Corporation analyst André Uddin. On Thursday, Uddin reiterated his “Speculative Buy” rating and $8.70 tar ...

Antibe Therapeutics has loads of upside, says Echelon Wealth

Echelon Wealth Partners analyst Douglas Loe is staying bullish on clinical stage drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart TSXV:ATE), reiterating his “Speculative Buy” rating and $1.40 target price in an update to clients on Tuesday. Toronto-based Antibe provide ...

Canopy Growth gets price target cut at PI, maintains “Buy” rating

With its latest quarterly earnings, Canopy Growth (Canopy Growth Stock Quote, Chart TSX:WEED) has shown itself to be the cannabis market leader in revenue but also in expenses, a result which has moved PI Financial analyst Jason Zandberg to drop his 12-month target for the stock. In a client update ...

Canopy Growth’s Corp’s long-term growth strategy is solid, GMP says

Canadian cannabis licensed producer Canopy Growth Corp. (Canopy Growth Corp. Stock Quote, Chart TSX:WEED) maintained its “Buy” rating with GMP Securities analyst Ryan Macdonell on Monday, despite the recent quarterly results which were mixed. Last Friday, Canopy reported Q4 2019 earnings that f ...

Keep the faith with Knight Therapeutics, this analyst says

Patience is a virtue, especially when it comes to specialty pharma name Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD), which has been testing investors with is go-slow approach to building up the company. But there’s nothing wrong with having a lot of cash on the balance sh ...

Organigram is a cheap pot stock, says Beacon Securities

Beacon Securities analyst Russell Stanley says that not only is cannabis name Organigram Holdings (Organigram Holdings Stock Quote, Chart TSXV:OGI) currently trading at a substantial discount to its broader peer group, on a technical basis the stock is now trading at levels that should offer strong ...